Key statistics
On Tuesday, Oruka Therapeutics Inc (HQ1:MUN) closed at 27.40, -7.43% below its 52-week high of 29.60, set on Jan 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 27.40 |
|---|---|
| High | 27.40 |
| Low | 27.40 |
| Bid | 27.40 |
| Offer | 27.80 |
| Previous close | 27.20 |
| Average volume | 3.78 |
|---|---|
| Shares outstanding | 48.41m |
| Free float | 45.41m |
| P/E (TTM) | -- |
| Market cap | 1.61bn USD |
| EPS (TTM) | -2.36 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:01 GMT.
More ▼
Announcements
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences
- Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
- Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Oruka Therapeutics Announces New Board Member and Board Transition
- Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Oruka Therapeutics to Present at Multiple November Investor Conferences
- Oruka Therapeutics Announces $180 Million Private Placement
- Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
- Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
More ▼
